Neurofilament light chain as a biological marker for multiple sclerosis: a meta-analysis study

References

• GrayEWilkinsANeurofilament changes in multiple sclerosis3NixonRAYuanACytoskeleton of the Nervous SystemNew YorkSpringer2011347377
   Google Scholar
• CompstonAMaking progress on the natural history of multiple sclerosisBrain2006129Pt 356156316477087
   PubMed Web of Science ®Google Scholar
• BjartmarCKiddGMörkSRudickRTrappBDNeurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patientsAnn Neurol200048689390111117546
   PubMed Web of Science ®Google Scholar
• van WaesbergheJHKamphorstWde GrootCJAxonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disabilityAnn Neurol199946574775410553992
   PubMed Web of Science ®Google Scholar
• KhalilMSalzerJCSF neurofilament light: A universal risk biomarker in multiple sclerosis?Neurology201687111068106927521432
   PubMed Web of Science ®Google Scholar
• DongDLXuZSChevrierMRCotterRJClevelandDWHartGWGlycosylation of mammalian neurofilaments. Localization of multiple O-linked N-acetylglucosamine moieties on neurofilament polypeptides L and MJ Biol Chem19932682216679166878344946
   PubMed Web of Science ®Google Scholar
• GnanapavanSGrantDMorantSBiomarker report from the phase II lamotrigine trial in secondary progressive MS – neurofilament as a surrogate of disease progressionPLoS One201388e7001923936370
   PubMed Web of Science ®Google Scholar
• PetzoldANeurofilament phosphoforms: surrogate markers for axonal injury, degeneration and lossJ Neurol Sci20052331–218319815896809
   PubMed Web of Science ®Google Scholar
• TeunissenCEKhalilMNeurofilaments as biomarkers in multiple sclerosisMult Scler201218555255622492131
   PubMed Web of Science ®Google Scholar
• KuhleJPlattnerKBestwickJPA comparative study of CSF neurofilament light and heavy chain protein in MSMult Scler201319121597160323529999
   PubMed Web of Science ®Google Scholar
• XuZHendersonRDDavidMMccombePANeurofilaments as biomarkers for amyotrophic lateral sclerosis: a systematic review and meta-analysisPLoS One20161110e016462527732645
   PubMed Web of Science ®Google Scholar
• MoherDLiberatiATetzlaffJAltmanDGPRISMA GroupPreferred reporting items for systematic reviews and meta-analyses: the PRISMA statementInt J Surg20108533634120171303
   PubMed Web of Science ®Google Scholar
• PolmanCHReingoldSCBanwellBDiagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteriaAnn Neurol201169229230221387374
   PubMed Web of Science ®Google Scholar
• StangACritical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analysesEur J Epidemiol201025960360520652370
   PubMed Web of Science ®Google Scholar
• HuXYangYGongDCerebrospinal fluid levels of neurofilament light chain in multiple system atrophy relative to Parkinson’s disease: a meta-analysisNeurol Sci201738340741427896490
   PubMed Web of Science ®Google Scholar
• QinXYCaoCCawleyNXDecreased peripheral brain-derived neurotrophic factor levels in Alzheimer’s disease: a meta-analysis study (N=7277)Mol Psychiatry201722231232027113997
   PubMed Web of Science ®Google Scholar
• AltintasATumaniHYaziciSLehmensiekVCSF biomarkers in tumefactive multiple sclerosis and other disease subtypesNeurology20148210P4129
   Google Scholar
• AlvarezEPiccioLTutlamNMyelin basic protein and neurofilament as biomarkers of treatment response in a Phase II add-on trial of rituximab for relapsing multiple sclerosisJ Neuroimmunol20122531–215
   Web of Science ®Google Scholar
• ArrambideGEspejoCEixarchHNeurofilament light subunit and evolution of clinically isolated syndrome (CIS) to multiple sclerosisMult Scler20131911132133
   Web of Science ®Google Scholar
• ArrambideGEspejoCTintoreMThe only certain measure of the effectiveness of multiple sclerosis therapy is cerebrospinal neurofilament level-NOMult Scler201521101240124226242692
   PubMed Web of Science ®Google Scholar
• EvertssonBLöfstromVManouchehriniaAHillertJKarrenbauerVNovel CSF biomarkers NFL and CXCL 13, relationship with other CSF parameters and disease variables in MSNeurology20178816P1385
   Google Scholar
• FitznerBHeckerMZettlUKMolecular biomarkers in cerebrospinal fluid of multiple sclerosis patientsAutoimmun Rev2015141090391326071103
   PubMed Web of Science ®Google Scholar
• GajofattoACalabreseMBenedettiMDMonacoSClinical, MRI, and CSF markers of disability progression in multiple sclerosisDis Markers201335668769924324285
   PubMed Web of Science ®Google Scholar
• GomezFOehningerCCerebrospinal fluid light neurofilaments as a therapeutic marker of response in modifying therapies disease in multiple sclerosisJ Neuroimmunol20142751–21920
   Web of Science ®Google Scholar
• GresleMMButzkuevenHShawGNeurofilament proteins as body fluid biomarkers of neurodegeneration in multiple sclerosisMult Scler Int2011201117
   Google Scholar
• HarrisVTuddenhamJSadiqSBiomarkers of multiple sclerosis: current findingsDegener Neurol Neuromuscul Dis20177192930050375
   PubMed Web of Science ®Google Scholar
• HousleyWJPittDHaflerDABiomarkers in multiple sclerosisClin Immunol20151611515826143623
   PubMed Web of Science ®Google Scholar
• HutchinsonMThe only certain measure of the effectiveness of multiple sclerosis therapy is cerebrospinal neurofilament level: CommentaryMult Scler201521101242124326242693
   PubMed Web of Science ®Google Scholar
• KhalilMEnzingerCLangkammerCCSF neurofilament and N-acetylaspartate related brain changes in clinically isolated syndromeMult Scler201319443644222917689
   PubMed Web of Science ®Google Scholar
• LyckeJNKarlssonJEAndersenORosengrenLENeurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosisJ Neurol Neurosurg Psychiatry19986434024049527161
   PubMed Web of Science ®Google Scholar
• SalzerJThe only certain measure of the effectiveness of multiple sclerosis therapy is cerebrospinal neurofilament level – YESMult Scler201521101239124025828757
   PubMed Web of Science ®Google Scholar
• SemraYKSeidiOAShariefMKHeightened intrathecal release of axonal cytoskeletal proteins in multiple sclerosis is associated with progressive disease and clinical disabilityJ Neuroimmunol20021221–213213911777552
   PubMed Web of Science ®Google Scholar
• Soelberg SorensenPSellebjergFNeurofilament in CSF-A biomarker of disease activity and long-term prognosis in multiple sclerosisMult Scler20162291112111327364323
   PubMed Web of Science ®Google Scholar
• TortorellaCIaffaldanoPDirenzoVCerebrospinal fluid neurofilament light chain (NFL) but not N-acetyl aspartate (NAA) predicts the evolution to multiple sclerosis (MS) of clinically isolated syndrome suggestive of MS (CIS)Neurology2011769A332A333
   Web of Science ®Google Scholar
• GrayERiceCNightingaleHAccumulation of cortical hyperphosphorylated neurofilaments as a marker of neurodegeneration in multiple sclerosisMult Scler201319215316122723571
   PubMed Web of Science ®Google Scholar
• BodiniBCalabresiPAFrom neurofilament research to multiple sclerosis clinical practice: Where do we stand?Neurology201788981681728148634
   PubMed Web of Science ®Google Scholar
• SchmiererKTozerDJPetzoldAAxonal damage in the making: neurofilament phosphorylation and magnetization transfer in multiple sclerosis nonlesional white matterNeurology2011769A358A358
   Web of Science ®Google Scholar
• EikelenboomMJPetzoldALazeronRHMultiple sclerosis: Neurofilament light chain antibodies are correlated to cerebral atrophyNeurology200360221922312552034
   PubMed Web of Science ®Google Scholar
• KaymakamzadeBTuncer KurneATumaniHLehmensiekVSayatGKarabudakREvaluation of neurofilament heavy chain levels in progressive multiple sclerosis patients: Preliminary resultsEur J Neurol201421697
   Web of Science ®Google Scholar
• KuhleJDisantoGLorscheiderJFingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosisNeurology201584161639164325809304
   PubMed Web of Science ®Google Scholar
• KuhleJNourbakhshBGrantDSerum neurofilament is associated with progression of brain atrophy and disability in early MSNeurology201788982683128148632
   PubMed Web of Science ®Google Scholar
• Mañé-MartínezMAOlssonBBauLGlial and neuronal markers in cerebrospinal fluid in different types of multiple sclerosisJ Neuroimmunol201629911211727725108
   PubMed Web of Science ®Google Scholar
• ModvigSDegnMRoedHCerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain predict multiple sclerosis development and disability after optic neuritisMult Scler201521141761177025698172
   PubMed Web of Science ®Google Scholar
• PetzoldAThe prognostic value of CSF neurofilaments in multiple sclerosis at 15-year follow-upJ Neurol Neurosurg Psychiatry201586121388139025616604
   PubMed Web of Science ®Google Scholar
• PetzoldATozerDJSchmiererKAxonal damage in the making: neurofilament phosphorylation, proton mobility and magnetisation transfer in multiple sclerosis normal appearing white matterExp Neurol2011232223423921958956
   PubMed Web of Science ®Google Scholar
• SalzerJSvenningssonASundströmPNeurofilament light as a prognostic marker in multiple sclerosisMult Scler201016328729220086018
   PubMed Web of Science ®Google Scholar
• KuhleJPlavinaTBarroCSerum and CSF neurofilament light levels predict long-term outcomes in multiple sclerosis patientsNeurology20178816S50005
   Google Scholar
• KuhleJMalmeströmCAxelssonMNeurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosisActa Neurol Scand20131286e33e3623763388
   PubMed Web of Science ®Google Scholar
• ArrambideGEspejoCEixarchHNeurofilament light chain level is a weak risk factor for the development of MSNeurology201687111076108427521440
   PubMed Web of Science ®Google Scholar
• BurmanJZetterbergHFranssonMLoskogASRaininkoRFagiusJAssessing tissue damage in multiple sclerosis: a biomarker approachActa Neurol Scand20141302818924571714
   PubMed Web of Science ®Google Scholar
• FialováLBartosASvarcováJZimovaDKotoucovaJMalbohanISerum and cerebrospinal fluid light neurofilaments and antibodies against them in clinically isolated syndrome and multiple sclerosisJ Neuroimmunol20132621–211312023870535
   PubMed Web of Science ®Google Scholar
• MartínezMAOlssonBBauLGlial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosisMult Scler201521555056125732842
   PubMed Web of Science ®Google Scholar
• PetzoldAEikelenboomMJKeirGAxonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up studyJ Neurol Neurosurg Psychiatry200576220621115654034
   PubMed Web of Science ®Google Scholar
• PiehlFKockumIKhademiMPlasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimodMult Scler20182481046105428627962
   PubMed Web of Science ®Google Scholar
• TortorellaCDirenzoVRuggieriMCerebrospinal fluid neurofilament light levels mark grey matter volume in clinically isolated syndrome suggestive of multiple sclerosisMult Scler20172481039104528537100
   PubMed Web of Science ®Google Scholar
• TrentiniAComabellaMTintoréMN-acetylaspartate and neurofilaments as biomarkers of axonal damage in patients with progressive forms of multiple sclerosisJ Neurol2014261122338234325228004
   PubMed Web of Science ®Google Scholar
• BartosALabajJKotoucovaJZimovaDBucilovaVDolezilDDetection of elevated concentrations of light neurofilament subunits in CSF of patients with multiple sclerosisMult Scler20101610S346
   Google Scholar
• VillarLPicónCCosta-FrossardLCSF immunological biomarkers associated with neurodegeneration in multiple sclerosisMult Scler20131911538539
   Web of Science ®Google Scholar
• MiyazawaIFujiharaKNakashimaIPetzoldASatoSItoyamaYHigh CSF-neurofilament heavy chain levels in neuromyelitis optica: distinction from multiple sclerosisMult Scler200612S226S226
   Google Scholar
• MadedduRFaraceCToluPCytoskeletal proteins in the cerebrospinal fluid as biomarker of multiple sclerosisNeurol Sci201334218118622362332
   PubMed Web of Science ®Google Scholar
• NorgrenNSundströmPSvenningssonARosengrenLStigbrandTGunnarssonMNeurofilament and glial fibrillary acidic protein in multiple sclerosisNeurology20046391586159015534240
   PubMed Web of Science ®Google Scholar
• VillarLMPicónCCosta-FrossardLCerebrospinal fluid immunological biomarkers associated with axonal damage in multiple sclerosisEur J Neurol20152281169117525324032
   PubMed Web of Science ®Google Scholar
• TeunissenCEIacobaeusEKhademiMCombination of CSF N-acetylaspartate and neurofilaments in multiple sclerosisNeurology200972151322132919365053
   PubMed Web of Science ®Google Scholar
• KuhleJLeppertDPetzoldANeurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosisNeurology201176141206121321346223
   PubMed Web of Science ®Google Scholar
• BrettschneiderJPetzoldAJunkerATumaniHAxonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosisMult Scler200612214314816629417
   PubMed Web of Science ®Google Scholar
• IwanowskiPLosyJNeurofilament light, anti-ganglioside M3 antibody and interleukin 18 in relapsing-remitting and primary progressive multiple sclerosisMult Scler J201622879879
   Web of Science ®Google Scholar
• KuhleJStitesTChenYCSF neurofilament light chain levels are markedly reduced by fingolimod in relapsing multiple sclerosisMult Scler J20131911559560
   Google Scholar
• NovakovaLZetterbergHAxelssonMNeurofilament light in serum for monitoring multiple sclerosis: A new quantitative tool for measuring disease activity and therapeutic responseEur J Neurol201724577
   Web of Science ®Google Scholar
• TortorellaCRomanoRDirenzoVCSF neurofilament as a potential surrogate marker of early and subclinical cognitive impairment in clinically isolated syndromes suggestive of multiple sclerosisMult Scler J20131911295296
   Web of Science ®Google Scholar
• BarroCDerfussTNägelinYHigh sensitivity serum neurofilament-light chain measurements correlate with disease activity and disability in multiple sclerosis and are reduced after immunomodulatory treatment interventionMult Scler201622843844
   Web of Science ®Google Scholar
• PiehlFKockumIKhademiMHigh sensitivity measurement of neurofilament-light levels in plasma demonstrates a significant reduction in multiple sclerosis patients starting fingolimodMult Scler J201622672
   Web of Science ®Google Scholar
• AnnunziataPCioniCde SantiLHeavy neurofilament phosphoforms in relapsing-remitting multiple sclerosis: correlation with MRI measures and clinical disabilityJ Neurol20062532615981079
   PubMed Web of Science ®Google Scholar
• ArrambideGEspejoCEixarchHNeurofilament light and fetuin-A in clinically isolated syndrome patients as predictors for conversion to multiple sclerosisMult Scler20101610S25S26
   Google Scholar
• BrandtAUPaulFFreingAOberwahrenbrockTPetzoldASerum neurofilament in patients with relapsing-remitting multiple sclerosisMult Scler J201117S269S270
   Google Scholar
• CechovaLBartosARicnyJIncreased neurofilament concentrations in cerebrospinal fluid in multiple sclerosisEur J Neurol201017229
   Web of Science ®Google Scholar
• DisantoGBarroCGiardielloAGobbiCZeccaCKuhleJSerum neurofilament light chain levels in MS: A promising biomarker of clinical and subclinical disease severityMult Scler201622845
   Web of Science ®Google Scholar
• GnanapavanSGiovannoniGMinagarAJaffeSInterferon beta-1a treatment in patients with relapsing-remitting multiple sclerosis elevates immunomodulatory marker soluble HLA-I but has no effect on the axonal marker, neurofilament, or disabilityMult Scler20101610S141S142
   Google Scholar
• GresleMShawGLiuYValidation of phosphorylated neurofilament-H as a serum biomarker of neurodegeneration in multiple sclerosis patientsMult Scler20101610S346
   Google Scholar
• KhalilMEnzingerCLangkammerCCSF neurofilaments and N-acetylaspartate in relation to MRI-metrics at 3T in clinically isolated syndromes suggestive of multiple sclerosisMult Scler20111710S266S267
   Google Scholar
• Koel-SimmelinkMJElkEJNorgrenNDijkstraCTeunissenCDevelopment of a multiplex assay for simultaneous measurement of neurofilament subunits in cerebrospinal fluid of patients with multiple sclerosisMult Scler200814S277
   Google Scholar
• KuhleJBarroCBrachatAHBlood neurofilament light chain levels are elevated in multiple sclerosis and correlate with disease activityMult Scler J201622828
   Web of Science ®Google Scholar
• KuhleJBarroCKapposLFingolimod significantly lowers neurofilament light chain blood levels in relapsing-remitting multiple sclerosis patients as compared with interferon beta-1a or placeboEur J Neurol20172461
   Web of Science ®Google Scholar
• KuhleJLeppertDPetzoldANeurofilament heavy chain in CSF correlates with relapse activity and clinical disability in multiple sclerosisMult Scler20101610S343
   Google Scholar
• KuhleJPetzoldARegeniterAMehlingMLindbergRKapposLHighly sensitive electrochemiluminescence-based immunoassay to determine the neurofilament heavy chain as a marker of axonal damage in multiple sclerosisMult Scler2009159S201S202
   Google Scholar
• LimETSellebjergFAltmannDCerebrospinal fluid neurofilament heavy chain levels in acute optic neuritis and multiple sclerosis patients treated with oral high-dose methylprednisoloneNeurology2004627A382
   Web of Science ®Google Scholar
• LimETSellebjergFSorensenTLCerebrospinal fluid neurofilament heavy chain levels in acute optic neuritis and multiple sclerosis patients treated with oral high-dose methylpredinoloneJ Neurol Neurosurg Psychiatry20047581215
   Web of Science ®Google Scholar
• NovakovaLAxelssonMKhademiMRelationships between CSF biomarkers of inflammation and degeneration in RRMS are also found in healthy controlsMult Scler20152311353354
   Google Scholar
• PetzoldAMaggioreCPlantGSerum neurofilament levels suggest axonal damage is more extensive in neuromyelitis optica than in neuromyelitis optica or multiple sclerosis optic neuritisMult Scler200814S285
   Google Scholar
• TortorellaCIaffaldanoPDirenzoVRole of cerebrospinal fluid neurofilament light chain and N-Acetyl Aspartate in predicting the evolution to multiple sclerosis of clinically isolated syndrome suggestive of multiple sclerosisMult Scler20101610S193
   Google Scholar
• TortorellaCRomanoRRuggieriMCognitive impairment is related to cerebrospinal fluid neurofilament levels in clinically isolated syndrome suggestive of multiple sclerosis. A Functional MRI Study (P04.104)Neurology201278Meeting Abstracts 1P04.104
   Google Scholar
• van der StarBWouterGKristelATesevDRuthHvan der ValkPNeurofilament light as a target for autoimmunity in multiple sclerosisJ Neuroimmunol20102281–2195
   Google Scholar
• VorobyevaAFominykhVZakharovaMGulyaevaNBiochemical markers of neurodegeneration in multiple sclerosisMult Scler2013191136922723575
   PubMed Web of Science ®Google Scholar
• BhanAJacobsenCMyhrKMNylandHLodeKFarbuENeurofilament light chain and disease progression in MSMult Scler201622272
   Web of Science ®Google Scholar
• FialováLBartosAŠvarcováJZimovaDKotoucovaJSerum and cerebrospinal fluid heavy neurofilaments and antibodies against them in early multiple sclerosisJ Neuroimmunol20132591–2818723632043
   PubMed Web of Science ®Google Scholar
• PetzoldABrassatDMasPTreatment response in relation to inflammatory and axonal surrogate marker in multiple sclerosisMult Scler200410328128315222692
   PubMed Web of Science ®Google Scholar
• NovakovaLZetterbergHSundströmPMonitoring disease activity in multiple sclerosis using serum neurofilament light proteinNeurology201789222230223729079686
   PubMed Web of Science ®Google Scholar
• DisantoGBarroCBenkertPSerum neurofilament light: A biomarker of neuronal damage in multiple sclerosisAnn Neurol201781685787028512753
   PubMed Web of Science ®Google Scholar
• HaghighiSAndersenOOdénARosengrenLCerebrospinal fluid markers in MS patients and their healthy siblingsActa Neurol Scand20041092979914705970
   PubMed Web of Science ®Google Scholar
• NorgrenNRosengrenLStigbrandTElevated neurofilament levels in neurological diseasesBrain Res20039871253114499942
   PubMed Web of Science ®Google Scholar
• RosengrenLEKarlssonJEKarlssonJOPerssonLIWikkelsøCPatients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSFJ Neurochem1996675201320188863508
   PubMed Web of Science ®Google Scholar
• NovakovaLAxelssonMKhademiMCerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosisJ Neurochem2017141229630427787906
   PubMed Web of Science ®Google Scholar
• NovakovaLAxelssonMKhademiMCerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosisMult Scler J20172316271
   PubMed Web of Science ®Google Scholar
• HåkanssonITisellACasselPNeurofilament light chain in cerebrospinal fluid and prediction of disease activity in clinically isolated syndrome and relapsing-remitting multiple sclerosisEur J Neurol201724570371228261960
   PubMed Web of Science ®Google Scholar
• NovakovaLAxelssonMMalmeströmCReduced cerebrospinal fluid concentrations of oxysterols in response to natalizumab treatment of relapsing remitting multiple sclerosisJ Neurol Sci20153581–220120626342940
   PubMed Web of Science ®Google Scholar
• ZhangYLiXQiaoJNeurofilament protein light in multiple sclerosisZhonghua Yi Xue Za Zhi200787392745274918167263
   PubMedGoogle Scholar
• MalmeströmCHaghighiSRosengrenLAndersenOLyckeJNeurofilament light protein and glial fibrillary acidic protein as biological markers in MSNeurology200361121720172514694036
   PubMed Web of Science ®Google Scholar
• KuhleJBarroCDisantoGSerum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severityMult Scler201622121550155926754800
   PubMed Web of Science ®Google Scholar
• DisantoGAdiutoriRDobsonRSerum neurofilament light chain levels are increased in patients with a clinically isolated syndromeJ Neurol Neurosurg Psychiatry201687212612925716934
   PubMed Web of Science ®Google Scholar
• KuhlmannTLingfeldGBitschASchuchardtJBrückWAcute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over timeBrain2002125Pt 102202221212244078
   PubMed Web of Science ®Google Scholar
• TrappBDBoLMörkSChangAPathogenesis of tissue injury in MS lesionsJ Neuroimmunol1999981495610426362
   PubMed Web of Science ®Google Scholar
• SilberEShariefMKAxonal degeneration in the pathogenesis of multiple sclerosisJ Neurol Sci19991701111810540030
   PubMed Web of Science ®Google Scholar
• AxelssonMMalmeströmCGunnarssonMImmunosuppressive therapy reduces axonal damage in progressive multiple sclerosisMult Scler2014201435023702432
   PubMed Web of Science ®Google Scholar
• OlssonBMalmeströmCBasunHExtreme stability of chitotriosidase in cerebrospinal fluid makes it a suitable marker for microglial activation in clinical trialsJ Alzheimers Dis201232227327622785399
   PubMed Web of Science ®Google Scholar
• GunnarssonMMalmeströmCAxelssonMAxonal damage in relapsing multiple sclerosis is markedly reduced by natalizumabAnn Neurol2011691838921280078
   PubMed Web of Science ®Google Scholar
• ConductierGBlondeauNGuyonANahonJLRovèreCThe role of monocyte chemoattractant protein MCP1/CCL2 in neuroinflammatory diseasesJ Neuroimmunol20102241–29310020681057
   PubMed Web of Science ®Google Scholar
• ComabellaMFernándezMMartinRCerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosisBrain2010133Pt 41082109320237129
   PubMed Web of Science ®Google Scholar
• Rysz-GórzynskaMGluba-BrzózkaASahebkarAEfficacy of statin therapy in pulmonary arterial hypertension: a systematic review and meta-analysisSci Rep201663006027444125
   PubMed Web of Science ®Google Scholar
• SuZZhuLWuJZhaoRJiHLHlJSystematic review and meta-analysis of nasal potential difference in hypoxia-induced lung injurySci Rep201663078027488696
   PubMed Web of Science ®Google Scholar